To predict gut microbial metabolism of xenobiotics and the resulting plasma concentrations of metabolites formed, an in vitro-in silico based testing strategy was developed using the isoflavone daidzein and its gut microbial metabolite S-equol as model compounds.
Introduction
The human intestinal tract is host to a diverse microbial community consisting of bacteria, yeasts, viruses, archaea, fungi and protozoa, of which anaerobic bacteria are dominating in number especially in the distal colon where the microbial density is the highest. [1] The gut microbiota is known to play an important role in the health of the host, among others through metabolism of indigestible food components, formation of vitamins and protection of the host from pathogens. [2, 3] While there are significant interindividual differences in the composition of the microbiota, these do not necessarily translate to functional differences. [4] Yet, dysbiosis of the gut microbiota is associated with various diseases, such as non-alcoholic fatty liver disease, metabolic disorders, inflammatory bowel disease, and autism. [5] [6] [7] [8] [9] The gut microbiota can further affect the susceptibility of its host to adverse effects caused by foodborne chemicals and pharmaceuticals by modifying their toxicity through a broad range of reactions, such as reduction, hydrolysis, dehydroxylation, acetylation, deacetylation, and N-oxide cleavage. [10, 11] To reduce the use of animal experimentation, toxicity testing is currently undergoing a paradigm shift away from the use of experimental animals towards the use of human-based in vitro experimentation combined with in silico modelling. At the heart of these testing strategies, physiologically based kinetic (PBK) models are used to describe the absorption, distribution, metabolism and excretion (ADME) to make sure kinetics are taken into account when using in vitro data to conclude on the in vivo situation. [12] With PBK modelling based reverse dosimetry, in vitro concentration-response curves can be translated to in vivo doseresponse curves that allow definition of points of departure that are required in risk assessment. In previous work we have shown proofs-of-principle for predicting, for www.mnf-journal.com
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example, liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine in rat [13] and human [14] , kidney toxicity of aristolochic acid I [15] and developmental toxicity of glycol ethers [16] , phenols [17, 18] , and all-trans-retinoic acid [19] . Currently established PBK models however, entirely ignore the gut microbiota, which may turn out an issue for compounds where metabolism by gut microbiota plays an important role in their ADME characteristics and/or toxicity. [12, 20] Currently established PBK models focus on the use of mammalian cell lines and tissue samples, yet entirely ignore the gut microbiota.
The isoflavone daidzein is an extensively studied example of a phytochemical that is affected by gut microbial metabolism. Daidzein is present in high levels in soybeans and soy products and is commonly consumed especially in Asian and vegetarian diets. [21] Microbial metabolism of daidzein yields dihydrodaidzein (DHD), which is subsequently further metabolized to S-equol and O-desmethylangolensin (O-DMA) by the gut microbiota ( Figure   1 ). [22, 23] The metabolite S-equol is reported to have a higher bioavailability and slower clearance than daidzein, [24] and to be a more potent inducer of estrogen receptors (ERs) than daidzein. [25] S-equol is reported to preferentially bind to ERβ over ERα. [26] Opposite to ERα activation, which is associated with adverse health effects through induction of cell proliferation, ERβ activation is associated with beneficial health effects through antiproliferative activities. [27] The microbial metabolite S-equol, however, is only produced by 20-35% of the Western adult population and 50-55% of the Asian adult population. [22, 28, 29] Most animal species are reported to be capable of producing S-equol, [30] which indicates that studies in laboratory animals might overestimate the effect of isoflavone ingestion when compared to the general human population. Importantly, S-equol-producing individuals are reported to benefit more from isoflavone ingestion than non-producers. [31] Some previous studies isolated different bacterial species from rat, mice and human capable www.mnf-journal.com
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of converting daidzein to DHD and/or S-equol [32] [33] [34] [35] , but these studies did not enable quantification of kinetic parameters required to include the gut microbial conversion of daidzein in PBK models.
In the present study, the metabolic rates of gut microbial metabolism of the model compound daidzein in rat were derived using anaerobic fecal incubations. Based on the kinetic data obtained, a PBK model described by Boonpawa et al. [36] was adapted to contain a gut microbial compartment, allowing to predict plasma concentrations not only of the isoflavone daidzein but also of its most important metabolite S-equol and relevant phase II metabolites. The predicted concentrations of these metabolites are compared to in vivo concentrations reported in literature.
Experimental Section

Materials and Standard Chemicals
Pooled Sprague Dawley (SD) male rat liver S9 was obtained from Corning (MA, USA 
Anaerobic incubation of rat faeces
Fresh fecal samples from Wistar rats (20 males and 20 females) were kindly provided by BASF (Ludwigshafen, Germany). Faeces were obtained by physical stimulation, weighed and immediately transferred into an anaerobic solution of 10% (v/v) glycerol in PBS and diluted to a final fecal concentration of 20% (w/v). Pooled samples were homogenized using a sterile glass wand, tubes flushed with N 2 gas and stored at -80 °C until further use.
Subsequently, samples were filtered using sterile gauze under anaerobic conditions, and aliquoted samples of resulting fecal slurry were stored at -80 °C until use.
Conditions for anaerobic incubation of rat faeces were optimized to achieve linear depletion of the substrate and linear formation of metabolites over time and concentration of faeces.
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Incubation solutions of 100 μL were prepared in anaerobic PBS containing 0.3% to 8% faeces (v/v), and 0.5% daidzein added from 200-times concentrated stock solutions in DMSO (final concentration 17.5 µM). Samples were prepared in an anaerobic chamber (Sheldon, Cornelius, USA) with an atmosphere of 85% N 2 , 10% CO 2 and 5% H 2 , and incubated in the same atmosphere at 37 °C. After incubation, 1 volume of ice-cold methanol was added to terminate the reaction. Subsequently, samples were put on ice for 10 min and centrifuged at 21,500 ×g for 15 min at 4 °C to precipitate microorganisms, particles, and proteins.
Quantification of the substrate and metabolites in supernatants was subsequently done using UPLC analysis performed as described below. For the kinetic incubations, 6% of faeces (replaced by 30% volume of PBS), respectively. These samples were prepared and processed in the same way as stated above. Incubations were repeated three times.
Glucuronidation of S-equol by rat liver S9
Incubations with pooled liver S9 fractions from male SD rats were performed as described by Islam et al. [37] with some modifications. Incubation mixtures of 100 μL were prepared containing 10 mM UDPGA, 0.025 mg/mL alamethicin (added from a 200-time concentrated stock solution in methanol) and 0.5 mg protein/mL rat liver S9 fractions in 50 mM Tris-HCl Supernatants were stored at -80 °C until UPLC analysis. Incubations were repeated three times.
UPLC analysis
UPLC analysis was performed to quantify the concentrations of daidzein and its metabolites.
The Waters ACQUITY UPLC system (Etten-Leur, The Netherlands) was equipped with a guard column and a Waters Acquity UPLC BEH C18 (1.7 μm, 2.1 × 50 mm) column. 0.1% TFA in nanopure water (v/v) was used as solvent A and ACN as solvent B. The injection volume was 3.5 μL and wavelengths of 190-320 nm were recorded using a Waters photodiode array detector.
For analysis of gut microbial metabolites, a flow rate of 0.3 mL/min was applied, and elution was performed using the following gradient: 0% B in 0-1.00 min; 0-25% B in 1.00-1.30 min; For the detection of rat liver S9 incubation products, a flow rate of 0.4 mL/min was applied, and elution was performed using the following gradient: 0-18% B in 0.20-0.40 min; 18% B for 0.20-3.00 min; 18-30% B in 3.00-3.50 min; 30-80% B in 3.50-5.00 min, 80-100% in 5.00-5.50 min, 100% B for 5.50-6.00, 100-0% B in 6.00-6.50 min and 0% B between 6.50-7.00 min.
To verify the type of conjugation, non-terminated samples were also prepared to incubate them with beta-glucuronidase to carry out the deconjugation reaction. Standard S-equol was used as a reference to allow quantification at the wavelength of 280 nm.
Kinetic analysis
Kinetic constants, including the apparent maximum velocity (V max ) expressed in µmol/h/g faeces and the apparent Michaelis-Menten constant (K m ) expressed in µM, were derived to describe the gut microbial conversion of daidzein and the glucuronidation of S-equol, using GraphPad Prism 5.04 (GraphPad Software, CA, USA). Data from rat faecal anaerobic incubations of daidzein and rat liver S9 incubations of S-equol were fitted to the standard Michaelis-Menten equation:
where v is the conversion rate and [S] represents the substrate concentration.
PBK model development
The schematic structure of the PBK model for daidzein and S-equol is shown in Figure 2 . This newly defined conceptual PBK model includes a main model for the parent compound daidzein, which involves separate compartments for blood, liver, fat, rapidly perfused tissue (e.g. heart, lung and brain) and slowly perfused tissue (e.g. skin, muscle and bone). This www.mnf-journal.com
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model was based on the model previously reported and validated for the related isoflavone genistein. [36] To simulate reactions in the intestine, the small intestinal lumen, intestinal tissue, and the large intestinal lumen are described as separate compartments, where the gut microbial metabolic activities are described in the large intestinal lumen. The conversion of daidzein by the gut microbiota results in the formation of three metabolites, DHD, Sequol and O-DMA. S-equol was modelled to directly enter the liver from the large intestinal lumen with the rate constant of 3.43/h, as the phase II metabolism of large intestinal tissue is considered negligible compared to that of the liver. To be able to predict the plasma concentrations of S-equol, being the most important metabolite due to its biological activity, a sub-model was prepared to describe its distribution and metabolism.
In order to develop a PBK model, three types of parameters are needed: (I) physiological and anatomical descriptors, (II) physico-chemical parameters such as partition coefficients of the compound and (III) kinetic parameters which describe the metabolic reactions. [20] Values for the first two classes of parameters are presented in Table 1 . Physiological parameter values such as tissue volumes and blood flows, were obtained from literature. [38] Tissue/blood partition coefficients were calculated based on the method reported by DeJongh et al. [39] using the octanol-water partition coefficient (Log P) of 2.51 and 3.20 for daidzein and S-equol, [40] respectively.
Kinetic parameters V max and K m defined in rat faecal anaerobic incubations as described above were used to describe gut microbial conversions from daidzein to DHD, S-equol and O-DMA, as was required for model development. To this end, rat faecal anaerobic incubations were carried out as described above. The obtained apparent V max values expressed in µmol/h/g faeces were scaled to the whole body using a fecal fraction of body weight 0.0164. [41] www.mnf-journal.com
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Kinetic constants of daidzein glucuronidation by liver and small intestinal tissue samples
were taken from published literature, [37] whereas formation of sulfated metabolites was considered to be negligible, since previous studies showed the catalytic efficiencies (V max /K m ) for sulfation to be at least two orders of magnitude lower than glucuronidation. [37] Kinetic constants for rat liver glucuronidation of S-equol were obtained by performing incubations with pooled SD male rat liver S9 fractions, carried out as described above.
V max values (nmol/min/mg protein) of glucuronidation in small intestine and liver were scaled to in vivo V max values, using an S9 protein yield of 38.6 and 143 mg/g tissue for small intestine and liver, respectively. These values were obtained from the sum of cytosolic protein yield of 18 and 108 mg/g tissue and microsomal protein yield of 20.6 and 35 mg/g tissue for small intestine and liver, respectively. [43] The scaled V max values and the catalytic efficiencies were calculated as followed:
Large intestinal lumen: 
Sensitivity analysis
A sensitivity analysis was performed using a relatively simple linear method [44] to assess which parameters of the PBK model have the largest impact on predicted maximum plasma concentrations (C max ) of daidzein and S-equol. Normalized sensitivity coefficients (SCs) were calculated according to the following equation: [44] 
where C stands for the initial value of model output; C´ is the modified value of model output with a 5% increase of an input parameter; P is the initial parameter value and P' is the parameter value with an increase of 5%. For sensitivity analysis, only one parameter is changed each time, while other parameters are kept at their initial values. A large SC value indicates a large impact of this parameter on predicted plasma C max of daidzein and S-equol.
Oral doses of 2, 38 and 80 mg/kg bw daidzein were used to carry out the sensitivity analysis, which are the reported highest daily intake in a Western diet, average daily intake in an Asian diet, and the highest dose when consuming soy supplements, respectively. [45] The linear sensitivity analysis now performed is a simple first tier approach aiming to provide initial information about which parameters influence the predicted C max values www.mnf-journal.com
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most, while a more extended analysis of variability in the thus identified most influential parameters, for example via example Monte Carlo modelling, might provide additional insight in intraspecies differences. [46] [47] [48] To further assess how gut microbial related kinetic parameters V max and K m affect plasma C max of daidzein and S-equol, a sensitivity analysis was performed using K m and V max values amounting to their mean value plus or minus the standard deviation (P' in the formula equals P plus or P minus the respective standard deviation).
Estrogen receptor-mediated chemical-activated luciferase gene expression (ER-
CALUX) assay of daidzein and S-equol
To assess the estrogenic potency of daidzein and S-equol, the reporter gene assay ERα-CALUX was performed, using the human osteosarcoma U-2OS ERα cell line which is stably expressing ERα in addition to a 3x estrogen response element (ERE) and TATA box binding protein combined with a luciferase gene as reporter. [49] Cells were cultured at 37°C in a humidified atmosphere and 5% CO 2 . Cell culture medium used was DMEM/F-12 (with phenol red) supplemented with 5% DCC-FCS (v/v), 1% NEAA
(v/v), and 1% penicillin streptomycin. Cultures were trypsinized and subcultured at a ratio of 1:6 to 1:8 twice per week, when grown to 70-80% confluence. Two days before plating of the cells to perform the assay, cells were exposed to 0.2 mM geneticin in the cell culture medium to exert selection pressure.
To perform the assay, cells were trypsinized and plated in the inner 60 This article is protected by copyright. All rights reserved.
was carefully aspirated and replaced by 100 μL fresh assay medium/well. After another 24 hours of incubation, assay medium was aspirated and 100 μL exposure medium was added.
Exposure medium consisted of test compounds in DMSO (0.5% final concentration) prepared from 200-times concentrated stocks in assay medium, and cells were exposed to 0.01-1,000 pM E 2 , 0.1-100,000 nM daidzein or 0. Flavonoids are known to exert post-translational effects on luciferase. [50, 51] To be able to correct the results of the ERα-CALUX for these effects, the post-translational effects of daidzein and S-equol on luciferase were studied in U-2OS Cytotox cells constitutively expressing luciferase. [52] In this assay, post-translational stabilization of luciferase leads to increased luciferase activity, and cytotoxicity leads to reduced luciferase activity. Cell www.mnf-journal.com
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culturing, plating and exposure conditions were identical to the ERα-CALUX assay described above. Experiments were also repeated three times.
The results of the ERα-CALUX assay were corrected for post-translational effects of the test chemicals on the reporter enzyme. To this end, chemical-induced changes to luciferase activity in the Cytotox assay relative to the solvent control were calculated, and the results of the ERα-CALUX were divided by the respective factors. A nonlinear regression was fitted to the data (three-parameter dose-response curve with a Hill slope of 1.0) to the corrected data to obtain the concentration-response curves for each compound, using GraphPad Prism 5.04.
Results
Clearance of daidzein in rat faecal anaerobic incubations
To assess gut microbial metabolism of daidzein, anaerobic incubations of daidzein with rat faeces were performed. www.mnf-journal.com
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This article is protected by copyright. All rights reserved. Table 2 . Of the three microbial metabolites, S-equol is formed with the highest catalytic efficiency, which is 1.3-and 15.7fold as high as that of DHD and O-DMA, respectively.
Kinetic constants of metabolite formation from daidzein in rat fecal incubations
Enzymatic conjugation of S-equol in incubations with pooled rat liver S9 fractions
Kinetic parameters for liver phase II glucuronidation of S-equol were determined by in vitro incubations of pooled rat liver S9 fractions, as glucuronidation is the major pathway of host phase II conjugation of S-equol. Two glucuronides of S-equol were formed at similar rates in these incubations (Figure 5) . glucuronide-1 and glucuronide-2, respectively ( Table 3 ). The catalytic efficiency for the formation of S-equol glucuronide-2 is 1.6-times higher than that for formation of glucuronide-1, especially because of a 1.6-fold lower K m .
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PBK modelling
Influence of microbial metabolism on plasma concentrations of daidzein and S-equol
PBK modelling was used to predict the effect of gut microbial metabolism on the plasma concentrations of daidzein and its metabolite S-equol in the host.
The results obtained provide a first proof-of-concept for including the gut microbiota as a separate compartment in the PBK model structure, confirming that only in this way occurrence of S-equol in host plasma can be predicted. This is clearly shown in Figure 6A which presents the predicted time dependent plasma concentration of S-equol for both the PBK model without and with the gut microbiota included. It can be seen that upon oral dosing of 20 mg/kg bw daidzein, S-equol is not present in the circulation when microbial metabolism is not included in the PBK model, since its plasma concentration remains zero.
Once microbial activity is introduced into the model, S-equol concentrations show a typical pharmacokinetic curve with a C max of 0.007 μM. This is a proof-of-concept that the current developed PBK model including microbiota as a separate compartment works.
The metabolic activity of gut microbiota marginally affects the plasma levels of daidzein ( Figure 6B) , where plasma C max of daidzein decreases from 2.19 to 2.16 μM, and the area under the concentration-time curve (AUC 0-4h ) reduces from 0.018 to 0.016 μmol h/L when microbial activity is introduced into the system.
Comparison of model predictions and in vivo data on daidzein and S-equol plasma concentrations
The plasma C max of unconjugated daidzein and S-equol predicted by the model were compared with in vivo plasma concentrations upon oral administration of 1.14-30 mg/kg bw daidzein reported in literature. [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] For the literature data reporting the concentrations of www.mnf-journal.com
Page 19 Molecular Nutrition & Food Research
daidzein and S-equol after hydrolysis, these data were corrected for the fractions of unconjugated daidzein and S-equol in the circulation (i.e. 8.1% and 1.1%, for daidzein and Sequol, respectively). [63] Figure 7 shows the ratio between the predicted plasma concentrations and the values reported in literature (details are presented in Supplementary Material 2) . There is considerable variation between the in vivo studies, and the predicted plasma C max of daidzein is on average 1.22 times the reported in vivo plasma C max . For S-equol, only two studies were found that could be included in this comparison, and based on these data the predicted plasma C max of equol is on average 1.07 times the predicted in vivo plasma C max .
Sensitivity analysis
To assess key parameters that influence the model output, in this case the plasma C max of daidzein and S-equol, a sensitivity analysis was carried out. Upon oral dosing of daidzein at 2, 38 and 80 mg/kg bw, parameters that appeared to have absolute normalized sensitivity coefficients (SCs) higher than 0.1 for at least one dose are presented in Figure 8 .
Results reveal that the normalized SCs for most of the PBK model parameters are dosedependent. The predicted plasma C max of daidzein is predominantly influenced by the absorption rate of daidzein to small intestinal tissue (Ka), the fraction of blood flow to rapidly perfused tissue (QRc), the fraction of liver tissue (VLc), the liver S9 protein yield (VLS9) and the V max for daidzein-7-O-glucuronide formation by the liver (VmaxLDAI7Gc) .
Similarly, for S-equol, parameters including QRc, VLS9 and VLc affect its predicted plasma C max to the largest extent. The parameters related to gut microbial activities have small effects on the plasma C max of daidzein, but considerable influence on the C max of S-equol.
Page 20 Molecular Nutrition & Food Research
Especially the V max and K m for formation of S-equol in the large intestine (VmaxLIEQUc and KmLIEQU) are of influence on the C max of S-equol.
Further analysis also confirmed that gut microbial kinetics V max and K m are influential parameters, where Supplementary Material 2. Table S3 shows that plasma C max of daidzein and S-equol changes, albeit still to a limited extent, when changing kinetic parameters according to their standard deviations.
Estrogenicity of daidzein and S-equol
The ERα-CALUX assay was performed to assess the estrogenic potency of daidzein and Sequol. Figure 9 shows the concentration-response curves of 17β-estradiol (E2), daidzein and S-equol. The respective effective concentrations to reach a 10% (EC 10 ) and 50% (EC 50 ) induction of ERα-mediated gene expression derived from these curves are listed in Table 4 .
The curves of daidzein and S-equol were corrected for post-translational effects on the luciferase enzyme quantified using the U-2OS Cytotox cells. The results obtained show that the gut microbial metabolite S-equol is a more potent estrogen than its parent compound daidzein, having a 6.3-and 12.7-fold higher potency when comparing EC 10 and EC 50 values, respectively.
Comparison of in vitro EC 10 and dietary resulting plasma concentrations
To obtain insight in the physiological relevance of the in vitro detected estrogenic activity of daidzein and S-equol the EC 10 values for ERα activation derived from the ERα-CALUX assay were compared to predicted rat plasma C max of daidzein and S-equol resulting from different dietary exposure scenarios. To this end, plasma C max values of daidzein and S-equol as a result of a typical Western diet (daily isoflavone consumption <2 mg/kg bw), [64] a Western www.mnf-journal.com
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vegetarian diet (daily isoflavone consumption approximately 12 mg/kg bw), [65] an Asian diet (daily isoflavone consumption 15-61 mg/kg bw) [66] [67] [68] and isoflavone supplement consumption (daily isoflavone consumption 20-80 mg/kg bw) [69] [70] [71] [72] were predicted using the developed PBK model. Predicted C max values obtained were converted to unbound concentrations by correcting for the protein unbound fractions in plasma, which are reported to be 12% [64] and 3.5% [73] for daidzein and S-equol, respectively. Figure 10 shows that for daidzein, predicted unbound plasma C max values resulting from all diets, except for the Western diet, were predicted to be generally higher than the EC 10 value of daidzein for ERα activation. Predicted unbound plasma C max values of S-equol resulting from different dietary intakes were generally lower than the EC 10 value of S-equol for ERα activation.
Discussion
The aim of the present study was to create an in vitro-in silico based testing strategy to predict gut microbial metabolism of xenobiotics and the resulting plasma concentrations of the metabolites formed, using the isoflavone daidzein and its gut microbial metabolite Sequol as model compounds. The anaerobic fecal incubations were optimized to establish a linear relationship of metabolites formed over fecal concentrations and time, to allow adequate kinetic experiments and definition of Michaelis-Menten parameters. To our knowledge, this is the first time that apparent V max and K m values are derived to describe the metabolism of a chemical by the gut microbiota, which are subsequently used for PBK modelling. Previous in vitro fecal incubations have reported microbial metabolism of daidzein and formation of S-equol. [32-34, 74, 75] However, from those studies no kinetic parameters could be derived, as the long incubation times in the reported studies lead to www.mnf-journal.com
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non-linear kinetics, which are in part due to microbial adaptation, usually resulting in exponential increases in metabolite degradation after a lag phase and/or depletion of the substrate at longer incubation times. [32] [33] [34] In the present study it was shown that non-linear kinetics could be avoided with use of diluted fecal slurries and only relatively shortincubation times. Fecal samples were used as a representative matrix for the colonic microbiota, since fecal communities are reported to be highly comparable to colonic ones in composition and function. [76] [77] [78] While there are certain differences in the microbial composition along the intestinal tract, the colon is housing the vast majority of microbes and is considered to be the most important contributor to the metabolic activity of the gut microbiota. Lagkouvardos et al. [79] performed a thorough review on the cultivation of bacteria from the intestine of mammals, and drew the conclusion that up to 65% of molecular species detected by sequencing have representative strains in culture under common culture conditions. In addition, the culture conditions in our study were designed to be as short as possible with as little enrichment as possible to be most representative of the intestinal communities and conditions when sampled, and were not intended to establish stable cultures. Thus, using fecal incubations to describe intestinal microbial metabolism provides a reasonable first tier approach, which, based on the result of the present study appeared to result in adequate predictions of the PBK model. This article is protected by copyright. All rights reserved.
predicted plasma C max being on average 1.22 and 1.07 times the in vivo plasma C max of daidzein and S-equol, respectively.
The analysis also revealed that both the reported and predicted plasma levels of S-equol are substantially lower than those of daidzein. In line with this, inclusion of gut microbial metabolism in the PBK model appeared to have only a marginal effect on the daidzein C max values, which leads to the suggestion that, in the case of isoflavones, models omitting the gut microbiota [36, 81] can still adequately predict concentrations of the parent isoflavone.
However, when metabolites with an increased toxicity or biological activity are formed, In line with literature, it was shown that S-equol is a more potent estrogen than daidzein (Figure 9) , so that the formation of S-equol is generally considered to be relevant for health effects associated with daidzein ingestion in humans. [75, 82] However, the results of the present study, comparing predicted plasma concentrations of unconjugated daidzein and Sequol with EC 10 values for ERα activation obtained in the ERα-CALUX assay, indicate that in rats the ERα-mediated estrogenicity is likely to be dominated by daidzein in spite of its microbial metabolite S-equol being more potent. It shall be noted that potential differences www.mnf-journal.com
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in protein binding between culture medium used in the ERα-CALUX assay and in plasma were not taken into account for this comparison, which might cause differences in free concentrations of daidzein and S-equol between these two systems. The free fraction in plasma of daidzein is reported to be 12% [64] while that for S-equol is 3.5% [73] , which further supports the conclusion that the contribution of S-equol to the in vivo estrogenicity of daidzein may be limited.
It is important to note that the PBK model developed in the present study relates to rats. This article is protected by copyright. All rights reserved.
In the current study, proof-of-principle for an in vitro-in silico based testing strategy to predict gut microbial metabolism of xenobiotics was developed, which could successfully be applied to predict the resulting plasma concentrations of an intestinal microbial metabolite in the host. This is a relevant addition to current QIVIVE strategies which are a key element of the 21 st century toxicity testing strategies. This article is protected by copyright. All rights reserved. Figure 7 . Ratio between the predicted plasma C max and the in vivo C max of unconjugated daidzein and S-equol upon oral dosing of 1.14-30 mg/kg bw daidzein. [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] This article is protected by copyright. All rights reserved. www.mnf-journal.com
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This article is protected by copyright. All rights reserved. Physiological parameters [38] Tissue: blood partition coefficients [39, 40] This article is protected by copyright. All rights reserved. 
